CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Polička, Czechia

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Study's Care of Acute Pancreatitis at Saint-Etienne University Hospital.

    Phase

    N/A

    Span

    47 weeks

    Sponsor

    Centre Hospitalier Universitaire de Saint Etienne

    Saint-Etienne

    Recruiting

  • Evaluation of First-void Urine as an Alternative to Cervical Sampling for Human Papillomavirus (HPV) Testing in Cervical Cancer Screening (Single-center Study).

    Phase

    N/A

    Span

    158 weeks

    Sponsor

    Centre Hospitalier Universitaire de Saint Etienne

    Saint-Etienne

    Recruiting

    Healthy Volunteers

  • CARE1 Pragmatic Clinical Trial

    In 2020, there were an estimated 431 288 new cases of kidney cancer (Renal Cell Carcinoma, RCC) globally with 138 611 cases in Europe, leading to 179 368 deaths worldwide, including 54 054 deaths in Europe (source: IARC/Globocan). To define high priority topics in academic research and launch dedicated trials, European RCC academic physicians have gathered into a European initiative - the CARE group. Systemic therapy for RCC relies on two classes of agents: anti-angiogenic targeted therapy (Vascular endothelial growth factor Tyrosine Kinase Inhibitor- VEGFR TKI) and immune checkpoint inhibitor (ICI), targeting either PD-1/PD-L1 axis or CTLA-4. Combination therapy is standard of care (SOC) for clear cell RCC in all guidelines with either ICI-ICI or ICI-VEGFR TKI. However, no head-to-head comparison have been performed between the two approaches and patients are treated based on physician decision without clinical or biomarker factors to guide treatment selection. PD-L1 staining is, to date, the biomarker that has demonstrated its ability to enrich for overall survival benefit favoring ICI-ICI strategy in PD-L1(+) and ICI-VEGFR TKI in PD-L1(-) patients. CARE1 PCT is a prospective randomize phase III study, in first line setting for patients with metastatic clear cell RCC comparing ICI-ICI vs ICI-VEGFR TKI approaches stratified on PD-L1 by local determination. Primary endpoint is overall survival (OS). The trial will enroll 1250 patients over 4 years across eight European countries (France, Spain, Netherlands, Czech Republic, Austria, Germany, Italy, UK) that are part of the CARE consortium. Study Sponsor is Gustave Roussy institute within the GETUG network for France, co-sponsor is developed through main academic networks (eg. SOGUG in Spain) and main institutions across Europe (eg. Cancer Core Europe - CCE). Study design has been develop to demonstrate that ICI-ICI is superior to ICI-VEGFR TKI in prolonging OS for PD-L1(+) patients and that ICI-VEGFR TKI is superior to ICI-ICI in prolonging OS for PD-L1(-) patients. CARE1 PCT has been designed and will be conducted with patient advocacy group representatives (ARTuR and IKCC) input. CARE1 is an academic phase III study designed to define the optimal combination using a pragmatic routinely implementable biomarker. Therefore, CARE1 will inform practice and has the potential to change treatment guidelines. Taken all together, CARE1 is a unique opportunity to build a large-scale platform to define new biomarker based therapy guidelines as well as to investigate quality of life, patient reported outcome and Health-Economic in front line setting, as well as pathological and blood biobank collection for further translational work. This action is part of the Cancer Mission cluster of projects on 'Diagnosis and treatment'.

    Phase

    3

    Span

    421 weeks

    Sponsor

    Gustave Roussy, Cancer Campus, Grand Paris

    Saint-Etienne

    Recruiting

  • A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

    Phase

    3

    Span

    298 weeks

    Sponsor

    Regeneron Pharmaceuticals

    Saint-Etienne

    Recruiting

  • Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

    To address these issues, for IFX or ADA therapy, several studies have proposed some algorithms according to which interventions are based on a combined assessment of IFX or ADA drug level and antibodies-to-IFX or ADA (ATI or AAA) levels at the time of therapeutic failure. Thus, IFX or ADA levels, classified as therapeutic or sub-therapeutic, and detectable or undetectable antibodies, are used to assess if LOR is likely due to immunogenicity, to non-immune-mediated pharmacokinetic problems or due to pharmacodynamic issues, and to guide interventions accordingly. In the last AGA recommendations, the authors suggested that in case of secondary LOR under anti TNF drug with therapeutic levels to switch to another class (such as vedolizumab). However, recent studies showed that optimization of dose regimen of the same anti-TNF in these patients may still be associated with clinical response in 25% of patients. Indeed, in a recent bicentric, retrospective and non-randomized study, the investigators showed that IBD patients under ADA maintenance therapy who experience a secondary loss of response and in whom trough levels are >4.9µg/mL, swapping to another class was significantly better than optimizing ADA, in term of time without discontinuation of treatment.

    Phase

    4

    Span

    118 weeks

    Sponsor

    Centre Hospitalier Universitaire de Saint Etienne

    Saint-Etienne

    Recruiting

  • Transcutaneous Vagus Nerve Stimulation as a Complementary Therapy to Exercise in Chronic Fatigue

    Phase

    N/A

    Span

    100 weeks

    Sponsor

    Centre Hospitalier Universitaire de Saint Etienne

    Saint-Etienne

    Recruiting

  • PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism

    The goal of this study is to provide quality data using standardized outcome definitions on postpartum bleeding events, venous thromboembolism (VTE) risk, delivery experience outcomes and health care utilization for intrapartum and postpartum anticoagulation management among pregnant individuals on low-molecular-weight heparin (LMWH) for prevention of treatment of VTE.

    Phase

    N/A

    Span

    352 weeks

    Sponsor

    University of Calgary

    Saint-Etienne

    Recruiting

  • Knowledge, Attitudes, Perceptions and Behaviors of Healthcare Professionals and the General Population Regarding Vaccination During Febrile Illness

    Phase

    N/A

    Span

    27 weeks

    Sponsor

    Centre Hospitalier Universitaire de Saint Etienne

    Saint-Etienne

    Recruiting

    Healthy Volunteers

  • Long Term Outcome of Easophageal Atresia : Transmics Profiles in Adolescence

    Phase

    N/A

    Span

    157 weeks

    Sponsor

    University Hospital, Lille

    Saint-Etienne

    Recruiting

  • Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

    Phase

    2

    Span

    182 weeks

    Sponsor

    Gilead Sciences

    Saint-Etienne

    Recruiting

1-10 of 28
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 703.538.7600
Toll Free: 888.838.5578

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information